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SUMMARY 
 
Background:  Rapid point of care MRSA screening (POCS) at hospital admission 
may be associated with a reduction in MRSA acquisition rates when compared with 
slower laboratory-based methods. We conducted a clinical trial to test this proposal. 
 
Methods:  A cluster randomised cross-over trial in four admission wards of an acute 
London tertiary care hospital. Polymerase chain reaction based POCS screening was 
compared with conventional culture screening. Patients were screened on ward 
admission and discharge and the MRSA acquisition rate on the admission wards was 
calculated as the primary outcome measure. 
 
Results: 10,017 patients were included; 4,978 in the control arm, 5,039 in the POCS 
arm. The MRSA carriage rate on admission was 1.7%. POCS reduced the median 
reporting time from 40.4 to 3.7 hours (P<0.001). MRSA was acquired on the admission 
wards by 23 (0.46%) patients in the control arm and 24 (0.48%) in the intervention arm, 
acquisition rates of 5.39 and 4.60 per 1000 days respectively. After taking account of 
predefined confounding factors, the adjusted incidence rate ratio (IRR) for change in 
trend for MRSA acquisition was 0.961 (95% CI 0.766-1.206).The adjusted IRR for step 
change for MRSA acquisition was 0.98 (0.304 - 3.162).  
 
Conclusions: POCS produces a significantly faster result but has no effect on MRSA 
acquisition on admission wards compared with culture screening. Where compliance 
with infection prevention and control is high and MRSA carriage is low, POCS has no 
additional impact on MRSA acquisition rates over the first 1-4 days of admission 
compared with conventional culture screening. 
 
 
 
 
Introduction 
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 Meticillin-resistant Staphylococcus aureus (MRSA) infections are associated 
with greater mortality, morbidity and healthcare costs than similar infections with 
meticillin-sensitive strains.1 MRSA is often endemic in healthcare settings and may 
be transmitted by person-to-person spread. Asymptomatic MRSA carriers are 
potential, unsuspected sources for transmission and some of them can be identified 
by admission screening.1 
 
 In England & Wales, the Health Act (2008) Code of Practice for the prevention 
and control of health care associated infections requires hospitals to have policies for 
MRSA admission screening and care pathways for the management of MRSA 
carriers.2 The identification, isolation and decontamination of patient carriers are 
associated with reduced MRSA transmission,3,4 although the evidence for this is 
limited and debated.5-7 
 
  Conventional laboratory-based culture screens (CS) take 2-3 days to report a 
result. More rapid detection of MRSA carriers theoretically should lead to faster 
implementation of control procedures and reduce the transmission of MRSA. 
Screening tests for MRSA using laboratory-based polymerase chain reaction (PCR) 
have significantly faster turn-around times (TATs) to result, averaging 22 hours.8 
However, although some studies comparing rapid and conventional screening at the 
same anatomical sites (the majority with nasal screens only) have shown an 
association between the use of laboratory-based PCR tests and a reduction in MRSA 
transmission and acquisition rates, others have not.4,7-12 The lack of effect in some 
studies may be because of continuing cross-transmission of MRSA during the 22 
hour delay before receiving the result of the laboratory-based PCR test. Much of that 
delay is due to the transit of the specimen between the ward and the laboratory. 
Because of the conflicting outcome results and the greater expense compared with 
CS, laboratory-based PCR tests have not been recommended for routine adoption in 
English hospitals.13   
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Point of care MRSA PCR screening tests (POCS) can be performed on the 
ward, eliminating specimen transit times and allowing a truly rapid result within about 
one hour. There have been no reports of controlled studies on this method. We 
therefore conducted a clinical trial to determine whether performing POCS on 
hospital wards where a good standard infection prevention and control was in place 
is associated with a reduction in MRSA acquisition rates compared with CS.  
 
For elective admissions, MRSA screening (and decontamination if necessary) 
is best done before hospital admission in outpatient clinics where rapid screening is 
unnecessary. Rapid screening is more appropriate for emergency admissions. In 
order to achieve better patient management, safety and resource utilisation, many 
hospitals, including our own, have introduced admission wards. Emergency patients 
are admitted to these wards for review, investigation and stabilisation before being 
either transferred to general wards or discharged to outpatient care.14 Stay on these 
wards is usually around 24-36 hours. MRSA screening of emergency hospital 
admissions is therefore ideally done on the admission wards. Since POCS can 
produce results within one hour, while CS takes 2-3 days, POCS will identify the 
MRSA status of patients before transfer or discharge and theoretically reduce 
transmission and acquisition within the general wards. Furthermore, since the 
postulated advantage of POCS is to reduce the 24-36 hour delay of culture 
screening, POCS should theoretically reduce MRSA transmission/acquisition on the 
admission wards themselves.  
 
The impact of admission ward screening on MRSA acquisition on general 
wards is dependent on numerous uncontrolled factors (including MRSA carriage by 
elective admissions and general ward transfers) and is difficult or impossible to 
measure with any accuracy. In contrast, the impact of rapid admission ward 
screening on MRSA acquisition within the admission wards themselves can be 
measured fairly accurately by screening at admission and on transfer/discharge and 
controlling for other variables by using a cross-over trial design. If POCS does have 
an impact on MRSA transmission compared with CS, then this should occur during 
the 22-36 hour stay on the admission wards; if it has no effect during this period than 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
it will have no advantage over culture or laboratory-based PCR screening. We 
therefore performed a controlled cluster-randomised cross-over clinical trial of POCS 
compared with CS on the four admission wards in our hospital, with MRSA 
acquisition on the admission wards as the primary outcome. 
 
 
 
Methods 
 
Setting 
 
 The study was performed in a 900 bed, acute NHS London teaching and tertiary 
care hospital between May 2011 and July 2012. Patients are admitted from the 
Emergency Department onto one of four admission units. After a period of assessment 
and treatment on these units, they are either discharged from the hospital or admitted 
to a general ward. For this study we screened patients on arrival at the admission 
wards, which were the two Medical Admissions Units (MAUs), the Acute Surgical Unit 
(ASU) and a Neurosurgical ward, the only study ward with a High Dependency Unit. 
The characteristics of the wards are shown in Table I. 
 
 
We used a cluster-randomised, controlled crossover trial design, with the four 
wards as clusters, randomised to control arm and intervention arm by a computer-
generated randomisation list. After the first phase of 7 months, there was a washout 
period for one month, followed by a second phase of 7 months, in which the wards 
were crossed over (Figure 1). Assuming a 3% MRSA carriage rate and a 0.3 
transmission rate, we estimated that a sample size of 3840 patients per study arm 
would have an 80% power (at the 5% significance level) to detect a 58% reduction in 
transmission rate, from 0.3 to 0.126.  
 
In accordance with Ethical Committee approval, all admitted patients were 
eligible for inclusion after providing informed verbal consent. Staff performing the 
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screening were trained in how to obtain consent and understood that patients could 
refuse.  
 
 
Intervention and control arms 
 
 During the control phase, admission screening was by CS only. During the 
intervention, patients were screened by both CS and POCS and both results were 
reported as soon as they were available. If the POCS returned an error/invalid result, 
the test was not repeated and interpreted as “not positive”. 
  
 For CS, pooled swabs from nose, throat and perineum were cultured in MRSA 
selective broth and MRSA Chromagar (Oxoid, Basingstoke, UK). Swabs from lesions 
at other sites were processed similarly. Meticillin susceptibility was determined by 
disc or automated testing (VITEK2; Biomérieux, Basingstoke, UK).  
 
 The intervention was POCS using the XpertTM MRSA system (Cepheid, 
Sunnyvale, CA, USA). A four-module Xpert system was installed in each of the study 
wards and POCS was performed by ward healthcare workers (HCWs) after training 
and confirmation of competency. Nasal swabs only were used for POCS, since these 
are the specimens licensed by the Food & Drug Administration for the system. Two 
nasal samples were taken simultaneously with double headed swabs (Copan, 
Brescia, Italy); one was used for CS and the other for POCS. Patients’ MRSA 
discharge status was assessed by CS on pooled nose, throat and perineum swabs. 
 
 Standard infection prevention and control (IPC) precautions were implemented 
for all patients, as well as pre-emptive isolation of patients judged at risk of MRSA 
carriage.12,15 MRSA positive patients were entered into an MRSA care pathway if they 
were known to be previously positive or as soon as a positive result was obtained 
from either POCS or CS; the management included decontamination and isolation (in 
side room, cohort bays or barrier isolation on wards, depending on the facilities 
available), following national guidelines.1,15  
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Data Collection 
 
 We collected patient demographics, date and time of admission and discharge 
and physical status on admission (using the American Society of Anesthesiology 
[ASA] scoring system).16 We collected potential ward confounding factors for MRSA 
transmission, including staffing levels; staff hand hygiene policy compliance 
(observed monthly); patient-days per month that MRSA positive patients were 
cohort/barrier isolated; and the MRSA importation pressure, defined as the proportion 
of patients positive for MRSA on admission per month. 
 
We regarded MRSA culture screening specimens taken within 48 hours of 
admission and 48 hours after discharge as valid screens for the study. Patients who 
stayed for less than 48 hours were included only if both admission and discharge 
culture screens were performed during their ward stay. Patients who were MRSA 
culture positive in any specimen taken up to five days before admission were 
classified as MRSA admission positive.  
 
 
 
Outcome Measures 
 
 The primary outcome was the MRSA acquisition rate (the proportion of 
patients MRSA negative on admission who subsequently became MRSA positive by 
the time of discharge). Secondary outcomes were (1) the MRSA transmission rate 
(the ratio of patients MRSA positive on admission to the number of MRSA 
acquisitions); (2) the MRSA acquisition rate per 1,000 patient days; (3) the TATs for 
the screening tests; and (4) the performance characteristics of POCS compared with 
CS. 
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Statistical Analysis  
 
 To assess the effect of the intervention on the primary outcome, we conducted a 
multilevel Poisson segmented regression allowing for ward-level random variation for 
baseline levels and time trends (from study start to end). We assessed step changes 
and changes in trends of MRSA acquisition rates per 100 patients at risk, in a model 
with a log link function adjusted by potential confounders (treated as continuous 
variables).  We included an offset term in the natural logarithm scale to account for the 
monthly exposure in each ward (i.e. the total number of patients at risk of acquiring 
MRSA [MRSA negative on admission] that were discharged monthly). The dependent 
variable was the monthly number of patients negative on admission who acquired 
MRSA during the ward stay. The significance of fixed effects was assessed through 
Wald tests. Measures of association for the fixed terms were summarized by adjusted 
Incidence Rate Ratios (IRR) per 100 patients at risk. The maximal random effect 
structure justified by the data was determined by comparing models accommodating 
increasingly complex random structures through log likelihood ratio tests. The analysis 
was conducted in R-3.1.1. statistical software using the package ‘glmmADMB’ to fit 
multilevel models by  Laplace approximation.17-19 For robustness, model coefficients 
were compared to those obtained using the Penalized Quasi-Likelihood estimation 
method (glmmPQL) in the ‘MASS’ package.20,21  
 
Results  
 
 There were 13715 admissions to the study wards, 6680 (48.7%) in the control 
arm and 7035 (51.3%) in the intervention arm; 760 (5.5%) were not screened by CS 
for MRSA on admission and were excluded, leaving a total of 12955 patients in the 
study, 6219 in the control and 6736 in the intervention arm (Figure 1). Of these 
12955, 222 (1.7%) were CS positive for MRSA on admission (or were known to be 
positive within the five days before admission) (control 113, 1.8%; intervention 109, 
1.6%). POCS was performed on 6414 intervention arm admissions (91.2% of total 
admissions). 
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With CS as the reference standard, the sensitivity of POCS was 68.8%, 
specificity 97.2%, Positive Predictive Value 28.8% and Negative Predictive Value 
99.5%. Error/invalid results occurred in 6.2% of tests and were excluded from this 
analysis. The median TAT from admission to reporting was 40.4 hours for CS and 3.7 
hours for POCS (P<0.001).  
 
Of the 12733 patients who were MRSA culture negative on admission, 2716 
(21.3%) were not correctly swabbed at discharge, due to either an oversight by staff 
or patients leaving the ward before the swabs were taken (control 1128, 18.5%; 
intervention 1588, 24.0%). Thus, there were 10017 patients who were CS negative on 
admission and had CS on discharge and were eligible for analysis (78.7% of all 
admissions screened by CS), 4978 control (81.5%) and 5039 intervention (76.0%) 
(Figure 1). The baseline patient and ward characteristics of patients in the two study 
wards were similar (Table II).   
 
MRSA was acquired by 47 (0.47%) of all 10017 patients eligible for analysis, 
23/4978 (0.46%) patients in the control arm and 24/5039 (0.48%) in the intervention 
arm (Table III). 
 
The total number of days that MRSA admission positive patients were not 
isolated was 257 (67% of their total stay of 378.3 days) in the control arm and 205 
(40.6% of their total stay of 504.8 days) in the intervention arm (P<0.001).   
 
There was no significant difference between patients in the control and 
intervention arms for age, gender, ASA score, study ward stay, days at risk for MRSA 
acquisition, being MRSA culture positive on admission but pre-emptively isolated 
before the positive result or length of ward stay of patients who were MRSA culture 
positive on admission. The segmented Poisson regression results showed that none 
of the confounding ward variables was a significant predictor of MRSA acquisition 
rate and no step change or trend change in MRSA acquisition rate was observed 
following the intervention. The results were consistent with those obtained when using 
the Penalized Quasi-Likelihood estimation method (data not shown). 
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Seven patients who were MRSA culture negative on admission and positive on 
discharge were POCS admission positive.  When these cases were excluded from 
the analysis, there was still no difference in the acquisition rates between the two 
arms. 
 
 
 
Discussion 
 
As in many other hospitals, we now have four acute admission wards for the initial 
admission and assessment of emergency patients, where they stay for around 1–3.5 
days (mean 2 days) before being discharged home or transferred to general wards. 
Admission MRSA screening of emergency patients is therefore ideally done on 
admission to the admission wards. Because conventional CS takes 2-3 days, some CS 
results became available only after patients have left the admission ward. Rapid POCS 
can produce results within about one hour and is faster even than laboratory-based 
PCR testing, which produces results in about 22 hours. POCS on admission wards 
therefore should theoretically facilitate the efficient management of MRSA carriers, 
allowing them to be placed on the MRSA pathway hours or days earlier than with other 
screening methods. This would be expected to reduce MRSA transmission and 
acquisition both on the admission wards themselves and then on the general wards. If 
POCS does not have an impact on transmission and acquisition while on the admission 
ward, it would have no advantage over CS wherever it is used.  
 
In order to test this hypothesis we performed a controlled clinical trial to measure 
the impact of POCS compared with CS on MRSA acquisition within the admission 
wards. We did this firstly because it is impossible to control for the numerous other 
factors that affect MRSA acquisition on general wards and secondly, if POCS does 
have a beneficial effect, it should be detectable within the first 24 - 48 hours. If it does 
not, then slower and cheaper screening methods would be appropriate. Furthermore, 
the risk of MRSA acquisition on the admission wards is significant; in the present study 
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there were about 20,000 patient hours of exposure to potential MRSA acquisition in 
each of the study arms. 
 
We used a cluster-randomised cross-over study to compare CS and POCS (the 
intervention) screening on the four admission wards. The POCS test was implemented 
satisfactorily by HCWs, with performance characteristics similar to those reported by 
others.22-25 When compared with CS, the Xpert MRSA specificity and NPV were good 
but the sensitivity and PPV were low. The low PPV result probably reflects a low 
prevalence of MRSA carriage at admission;26 other possible contributory factors include 
poor sampling, detection of non-viable organisms, detection of meticillin resistance 
genes in other organisms such as coagulase-negative staphylococci or in gene 
fragments, or non-specific amplification.11 The extra numbers of MRSA positive patients 
reported by POCS, compared with CS would have tended to increase rather than 
decrease early MRSA control for patients screened by POCS. However, the low 
sensitivity of POCS compared with CS reduced the proportion of CS positive patients 
that were detected more rapidly by POCS.   
 
POCS produced significantly faster results than laboratory-based CS by some 37 
hours, facilitating the much earlier implementation of appropriate MRSA control. As a 
result, in the control arm MRSA positive patents were isolated for 33% of their total stay 
while in the intervention arm positive patients were isolated for 59% of their total stay. 
The reason the positive patients in the intervention arm were not isolated for closer to 
100% of their stay was that the POCS test had poor sensitivity (68.8%) when CS was 
used as the standard. This meant that around 30% of the CS-positive patients were not 
detected by POCS and were therefore not isolated until the CS result was returned.   
 
Despite there being no significant difference between the control and intervention 
arms for patient age, gender, ASA score, length of ward stay, patient days at risk of 
MRSA acquisition or pre-emptive isolation, and allowing for variations in background 
MRSA importation pressure, staffing levels and compliance with hand hygiene, there 
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was no significant change in the MRSA acquisition rate following the intervention. Thus, 
we found no evidence to support the hypothesis that rapid POCS of patients on 
admission wards reduces rates of MRSA acquisition, and hence transmission on those 
wards compared with conventional, laboratory-based CS. POCS reduced the time that 
MRSA positive patients were not isolated compared with CS, but this did not reduce 
MRSA acquisition. 
 
 
A cluster-randomised cross-over study was an appropriate design for this trial 
but it may have been under-powered. The MRSA importation pressure and the 
transmission and acquisition rates in the control arm were lower than expected and, 
although MRSA screening on the admission units best reflects present hospital 
practice, it limited the number of clusters for analysis. Although there were four 
clusters per arm, which is the required minimum, a larger number would have been 
desirable; with each ward as its own control it is not possible to ensure with four 
clusters that the two arms remained balanced over time.  
 
Our study has some limitations. Only about three quarters of eligible patients had 
full admission and discharge screen data and, although there were about 5000 patients 
with full data sets in each arm, it is possible that we were unable to detect a small effect 
because rates of both MRSA carriage and transmission were low. The average length 
of stay on the admission wards was approximately 2 days and it can be argued that we 
may not have detected MRSA transmission by culture during this period; on the other 
hand, this is the time during which POCS would be expected to have a greater impact 
than CS. POCS significantly reduced the number of days that MRSA positive patients 
were not isolated compared with CS but this effect was reduced by the fact that the 
sensitivity and PPV of POCS on nasal swabs compared with CS on pooled multiple site 
swabs was low. These low values were partly the result of the low prevalence of MRSA 
carriage, but may also have been because (in culture studies) nasal swabs detect only 
around 80% of carriers compared with swabbing at multiple sites.9 This is an inherent 
problem with this POCS test because it is licenced by the FDA for nasal swabs only. 
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In the present study the MRSA carriage rate at admission measured by CS was 
1.71%. This is much lower than the rate of 6.7% found by CS in London hospitals in 
2006-7,5,8 but similar to the 1% result of a one week national prevalence study of MRSA 
screening in English NHS hospitals in 2011.27 This decline in MRSA admission carriage 
reflects the overall fall in MRSA infection rates in English hospitals associated with a 
national programme of targeted improvements in MRSA prevention and control.13 The 
lack of effect of rapid POCS in the present study may have been due to the low MRSA 
carriage rate at admission combined with good standard IPC practice, including pre-
emptive isolation of higher risk patients.  
  
It is likely that in a setting of low MRSA admission prevalence, good IPC can 
prevent most MRSA transmissions, even without admission screening, whether by 
standard or rapid methods.7,10,12 Furthermore, Robotham et al have shown in 
mathematical modelling studies that universal admission and weekly screening using a 
PCR MRSA test coupled with isolation is unlikely to be cost effective unless the 
prevalence is high.28 
 
Although the effectiveness of universal MRSA screening of all admissions has 
long been debated,4-7 the Department of Health (England) previously recommended that 
hospitals should screen all admissions.29.However, in 2014, the Department revised its 
guidance and recommended targeted screening of only high risk patients.13 This view is 
supported by the present study, which has shown that there is presently a very low 
prevalence of MRSA carriage at admission in London.   
 
In conclusion, there is growing evidence that in an environment where 
compliance with appropriate MRSA IPC procedures is high and the prevalence of 
MRSA carriage is low, rapid MRSA admission screening has no additional impact on 
MRSA acquisition and transmission compared with standard CS. The results of the 
present trial suggest that this is not only true for laboratory-based PCR tests but also for 
very rapid POC PCR screening. Our study does not support the introduction of point of 
care MRSA admission screening as a routine.  
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Table I  Characteristics of study wards 
 
Ward  Speciality No. of beds                   in bays 
Side
rooms 
Total 
beds 
Acute Surgical Unit (ASU, 6 
bays) 28 3 31 
Medical Admissions Unit 1 
(MAU 1, 6 bays) 24 6 30 
Medical Admissions Unit 2 
(MAU 2, 6 bays) 24 6 30 
Neurosurgical ward  with High 
Dependency Unit (4 bays) 21 10 31 
 
 
Table II 
Baseline characteristics of all patients in the control and intervention wards (all 
differences between the control and intervention wards were non-significant) 
Characteristics Control wards  Intervention wards  
Median (interquartile range) age in 
years 
57.2   
(40.3 - 75.4) 
58.7  
(41.0 - 76.5) 
Women (%) 3155           
(47.2) 
3367        
(47.9) 
Median (interquartile range) ASA 
score*  
2                 
(2 - 3) 
2              
(2 - 3) 
Median (interquartile range) 
study ward stay in days 
1.9        
(1.0 - 3.6) 
2.0         
(1.0- 3.7) 
Number of patients screened on 
admission or known to be MRSA 
positive 
6219 
 
6736 
Number patients MRSA positive at  
admission (% of screened 
admissions) 
113 (1.8%) 
 
109 (1.6%) 
MRSA culture positive on admission 
but pre-emptively isolated before 
positive result (% of all positives) 
33           
(29.2) 
48           
(44.0) 
Median (interquartile range) study 
ward stay for patients who are MRSA 
culture positive on admission 
2.0      
(0.9 - 4.9) 
3.0       
(1.3 - 4.9) 
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Number of patient-days that 
MRSA-negative patients were 
at risk of MRSA acquisition 
20956 23704 
 
*American Society of Anesthesiology score for physical status: from 1 (completely 
healthy) to 5 (moribund, not expected to live 24 hours)16. 
 
 
 
Table III   
Results for meticillin-resistant Staphylococcus aureus (MRSA) acquisition and 
transmission rates 
 
Variables Control arm  Intervention arm Total 
Number of patients who were screened by 
CS on admission (or were known to be 
positive) and discharge (%) 
4978 
(74.5) 
5039 
(71.6) 10017 
Number of patients MRSA positive by CS 
on admission (or were known to be 
positive) (%) 
113 
(1.8) 
109 
(1.6) 
222 
(1.7) 
Number of patients who acquired MRSA 
by discharge (MRSA acquisition rate, %) 
23 
(0.46) 
24 
(0.48) 
47 
(0.47) 
Acquisition per 1,000 patient-days 5.39 4.60 4.97 
Transmission rate 0.20 0.22 0.21 
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Figure 1.  Flow chart of the cross-over trial 
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94.0 %)
 
*Patients
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days before hospital admission 
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